Exogenous Antigens Gain Access to the Major Histocompatibility Complex Class I Processing Pathway in B Cells by Receptor-mediated Uptake

By Yong Ke and Judith A. Kapp

Summary

Professional antigen-presenting cells, such as macrophages, dendritic cells, or B cells, take up soluble, exogenous antigens (Ags) and process them through the class II pathway. Several reports have shown that phagocytic macrophages also process particulate or soluble forms of exogenous Ag via the class I pathway. By contrast, B cells normally do not process soluble, exogenous Ag by way of the class I pathway unless Ags are directly introduced into the cytoplasm. Here we report that B cells present exogenous Ag via the class I pathway when Ags are taken up by receptor-mediated endocytosis. Thus, specialized methods of Ag uptake such as phagocytosis or receptor-mediated endocytosis deliver exogenous Ag into the class I pathway of Ag processing and presentation.

Materials and Methods

Antigens and Reagents. Chicken egg OVA, TNP, chloroquine, brefeldin A, and phenazine methosulfate (PMS) were purchased from Sigma Chemical Co. (St. Louis, MO). Crystallized beef insulin was purchased from Lilly Research Labs (Indianapolis, IN). TNP was conjugated to OVA or insulin as described (13). Tetrazolium salt XTT was obtained from Diagnostics Chemicals Ltd. (Oxford, CT). N-acetyl-L-leucinyl-L-leucinal-L-norleucinal (LLnL) and N-acetyl-L-leucinyl-L-leucinal-methional (LLM) were provided by Dr. K.L. Rock (Harvard University, Boston, MA).

Antibodies. Culture supernatants from B cell hybridomas were used as sources of mAb. Anti-SP6 is a mAb specific for the idiotype of IgM,TNP (provided by Dr. N. Hozumi, University of Toronto, Toronto, Ontario, Canada). MK-D6 (anti-I-A^d) was obtained from the American Type Culture Collection (Rockville, MD). DO4 (anti-K^d), 25-9-35 (anti-I-A^b), and 270-JS (anti-K^b) were provided by Dr. V. Hauptfeld (St. Louis University, St. Louis, MO).

Cells and Cell Cultures. A HAT-sensitive variant of M12.4.1 (H-2a), a B cell lymphoma producing surface IgG of unknown specificity (14), was provided by Dr. R. Asofsky (National Institutes of Health, Bethesda, MD). F8.11 is a B cell hybridoma produced by fusion of M12.4.1 and spleen cells from C57BL/6 (H-2b) mice (15). SP6/HL is a B cell hybridoma provided by Dr. Hozumi. It secretes IgM, specific for TNP, and it reacts with the anti-SP6 mAb directed toward idiotypic determinants (16). E.G7-OVA (provided by Dr. M.J. Bevan, University of Washington, Seattle, WA) was produced by transfection of EL4 (H-2b) with the OVA cDNA gene (17). EL4-INS was produced in our laboratory by transfecting EL4 with the genomic human insulin gene (18). Two T cell hybridomas, 4B10 (CD8^+), specific for R£-
restricted OVA\textsubscript{257-264} and 2D5 (CD4\textsuperscript{+}, specific for I-\texttextsuperscript{A\textsubscript{2}}-restricted OVA\textsubscript{257-264}) (15), were used as reporter systems for the class I and class II presentation of OVA, respectively. An insulin-specific, CD8\textsuperscript{+}, MHC class I-restricted CTL line was generated by priming C57BL/6 mice with beef insulin in CFA and stimulating with EL4-INS as we described previously (18). All cells were cultured in RPMI 1640 containing 10% FCS, 1 mM l-glutamine, 1 mM Na-pyruvate, 50 \mu M 2-ME at 37°C in 6% CO\textsubscript{2} in air.

Vector and Gene Transfer. F8.11 cells were transfected with pRH-L\textsubscript{TNP} vector containing the structural genes for the \(\mu\) and \(\kappa\) chains of TNP-specific IgM from SP6/HL and the neomycin-resistance gene (19). G418-resistant transfecants, designated as F8.11HL, were selected and cloned by limiting dilution.

Measurement of Abs. Secretion of TNP-specific Ab by various cell lines was tested by ELISA. In brief, microtiter plates were coated with OVA or TNP-OVA and then blocked with PBS plus 1% BSA. Serially diluted supernatants were added and incubated at 37°C for 1 h. Alkaline phosphatase-conjugated goat anti-mouse IgM was then added and incubated at 37°C for 1 h. Finally, p-nitrophenyl phosphate substrate was added, and colorimetric reaction was read as absorbance at 405 nm using an automatic microplate reader ( Molecular Devices, Menlo Park, CA).

Ag Presentation Assay. In most experiments, IL-2 production by T cell hybridomas was used as a measure of Ag-induced activation. T cells were cocultured with irradiated (10,000 rads) B cell hybridomas in 96-well plates with or without Ag. In some cases, B cell hybridomas were pretreated with mAbs or inhibitors before incubation with Ag and T cells. Supernatants were harvested after a 24-h incubation at 37°C, and IL-2 production was tested with HT-2 cells (20) by using XTT plus PMS (21). Absorbance was read at 450 nm, and data were averages of triplicates ± SD. Representative experiments that have been repeated at least three times are shown.

Cytotoxicity Assay. Cytotoxicity assays were performed with \(^{51}\)Cr-labeled B cell hybridomas as targets and insulin-specific CTLs as effectors (18). Labeled target cells were plated in 96-well round-bottomed plates at \(10^4\) cells per well and incubated with various concentrations of Ag at 37°C for 1 h. CTLs were then added to the plates at an E/T ratio of \(1:10\). After a 4-h incubation at 37°C, supernatants were harvested, and radioactivity was detected in a gamma counter (Wallac, Turku, Finland). The percentage specific lysis equals \(100 \times \frac{[\text{release by CTLs} - \text{spontaneous release}]}{[\text{maximal release} - \text{spontaneous release}]}\). Maximal release was determined by addition of 1% Triton X-100. Spontaneous release in the absence of CTLs was <15% of maximal release. Representative experiments that have been repeated at least three times are shown.

Results and Discussion

Characterization of B Cells Expressing Anti:TNP mIg Receptors. B cells, like most other somatic cells, do not efficiently take up and process soluble, exogenous Ag into the class I pathway (1). The purpose of these studies was to determine definitively whether B cells can take up and process exogenous Ag via the class I pathway if Ag uptake is facilitated by receptor-mediated endocytosis. For this purpose, we wanted to use a B cell line that expresses high levels of membrane Ig (mIg) of a known specificity. We thought it was also important that the mIg-expressing B cells should not secrete significant amounts of Ab, because formation of Ag–Ab complexes would introduce ambiguities into the interpretation of these experiments. For example, such complexes might decrease the amount of available Ag or alternatively increase the amount of Ag taken up if B cells expressed FcR. Therefore, we chose M12.4.1 B cell lymphoma for the starting cells. This tumor arose in BALB/c mice and expresses both MHC class I and MHC class II Ag (14). In addition, M12.4.1 expresses mIgG of an unknown specificity (J.A. Kapp, unpublished observations) but does not secrete Ig (14). A HAT-sensitive variant of M12.4.1 was fused with SCs from C57BL/6 mice injected with LPS. This fusion gave rise to a hybridoma (F8.11) that expresses MHC class I and class II Ag from both H-2\textsuperscript{b} and H-2\textsuperscript{d} haplotypes (15).

F8.11 was subsequently transfected by electroporation with a plasmid (pRH-L\textsubscript{TNP}) containing the rearranged \(\mu\) and \(\kappa\) genes cloned from genomic DNA of SP6/HL (19). Hozumi and colleagues have previously shown that transfection of B cell hybridomas with this plasmid yielded cells that secreted TNP-specific IgM (16). By contrast, transfection of A20-2J, a B lymphoma line, with this construct produced cells expressing TNP-specific mIgM (19). Thus, these results illustrate that the phenotype of the recipient cell dictates differential mRNA processing of the \(\mu\) chain (22, 23). Neomycin-resistant transfectants were identified by rosette formation with TNP-conjugated sheep RBCs and binding of fluoresceinated anti-SP6, an idiootype-specific...
cific Ab (not shown). The transfecent (F8.11HL) that was selected for cell surface expression of anti-TNP Ig was tested for secretion of IgM_{TNP} (sIg). Supernatants were tested for TNP-specific Abs by ELISA. SP6/HL secreted anti-TNP Abs, whereas neither F8.11 nor F8.11HL did so (Fig. 1), indicating that F8.11HL cells produce mlgM_{TNP} but not sIgM_{TNP}. Thus, F8.11HL could be used to provide APCs without concern that secreted Ab might interfere with the interpretation of the results.

B Cells Expressing mlg Receptors Process Exogenous Ag via The Class I Pathway. The ability of mlg-bearing B cells to present exogenous Ag via the class I pathway was first tested by using the OVA_{257-264}-specific, CD8\(^{+}\), K\(^{b}\)-restricted T-cell hybridoma 4B10. Stimulation of 4B10 by F8.11HL was dose dependent when incubated with TNP-OVA but not native OVA (Fig. 2 A), whereas B cells lacking mlg_{TNP} receptors (F8.11) did not stimulate 4B10 with either OVA or TNP-OVA (Fig. 2 C). These data suggest that uptake of TNP-OVA into the class I pathway was mediated by mlgM_{TNP} receptors. For comparison, the ability of F8.11 and F8.11HL to process Ag via the class II pathway was tested with the OVA_{265-271}-specific, CD4\(^{+}\), I-A\(^{b}\)-restricted T-cell hybridoma 2D5. As expected, both F8.11HL (Fig. 2 B) and F8.11 (Fig. 2 D) presented TNP-OVA and OVA to 2D5. As shown by others (10, 19, 24), B cells bearing specific receptors presented haptenated Ag to CD4\(^{+}\) T cells more efficiently than unmodified Ag (Fig. 2 B). B cells lacking mlgM_{TNP} receptors presented haptenated and unmodified OVA to 2D5 equally well (Fig. 2 D). It should be noted that presentation of TNP-OVA by F8.11HL to CD4\(^{+}\) T cells (2D5) was ~100-fold more efficient than presentation to CD8\(^{+}\) T cells (4B10).

We wanted to determine whether presentation of exogenous Ag via the class I pathway by mlgM_{TNP}-bearing B cells was unique for OVA or generalizable. Thus, these experiments were repeated with an insulin-specific CTL line (18). As shown in Fig. 3 A, F8.11HL cells pulsed with TNP-insulin, but not unmodified insulin, were killed by the CD8\(^{+}\) CTL. F8.11HL cells pulsed with TNP-OVA were not killed by the insulin-specific CTLs (not shown). By contrast, F8.11 cells pulsed with either TNP-insulin or insulin were not killed by these CTLs (Fig. 3 B). These results demonstrate that processing via the class I pathway is not unique to OVA. Moreover, these data show that processing via the class I pathway renders B cells susceptible to lysis by CTLs.

Inhibition of Class I or Class II Presentation of Exogenous Ag by B Cells. To verify that mlgM_{TNP} receptors were responsible for class I presentation of TNP-OVA, F8.11HL cells were pretreated with anti-Id mAb. Anti-SP6 inhibited presentation of TNP-OVA to both CD8\(^{+}\) (Fig. 4 A) and CD4\(^{+}\) T cells (Fig. 4 B). As expected, anti-SP6 did not inhibit presentation of native OVA to CD4\(^{+}\) T cells, since uptake is by endocytosis and not facilitated by mlg recep-
Several inhibitors were used to determine whether presentation of TNP-OVA followed the classically defined pathway for class I or class II processing. The class I inhibitor brefeldin A (25) blocked presentation of TNP-OVA by F8.11HL to CD8<sup>+</sup> 4B10 (Fig. 4 E) but not to CD4<sup>+</sup> 2D5 (Fig. 4 F). By contrast, weak bases such as chloroquine inhibited presentation of TNP-OVA by F8.11HL to 2D5 (Fig. 4 E) but not to 4B10 (Fig. 4 E). Recently, Rock et al. showed that class I processing of electroporated OVA was inhibited by peptide aldehyde LLnL but not by LLM, a closely related analogue (26). Although both aldehydes are reported to inhibit lysosomal proteases, several lysosomal inhibitors failed to inhibit the class I pathway (26). Thus, these authors concluded that proteasomal processing generates the peptides presented by MHC class I molecules. Our data show that class I processing of TNP-OVA taken up by receptor-mediated endocytosis was similarly inhibited by LLnL but not by LLM (Fig. 4 E), whereas class II processing of TNP-OVA was inhibited by both LLnL and LLM (Fig. 4 F). The latter observation is not surprising, given that both aldehydes are potent inhibitors of lysosomal processing (26). Neither LLnL nor LLM inhibited presentation of OVA<sub>257-264</sub> or OVA<sub>265-289</sub> peptides to CD8<sup>+</sup> or CD4<sup>+</sup> T cells, respectively. Thus, these inhibitors are not nonspecifically toxic (not shown).

The present study suggests that exogenous Ags taken up by ligand-mediated endocytosis of mlg receptors are shuttled from the endosomal compartment into the cytosol for class I processing. Barnaba et al. reported that hepatitis B envelope (Hbenv)-specific B cells presented exogenous Ag to Hbenv-specific MHC-restricted CD8<sup>+</sup> T cells (27). However, normal B cells also presented Hbenv, unlike our findings for OVA. These investigators have shown that the transferrin receptor (TfR) is required for the uptake and processing of Hbenv into the class I and class II pathways by activated human T cells (28). Moreover, uptake via the TfR requires binding of Hbenv to transferrin (29). This pathway of peptide binding by transferrin and subsequent uptake by TfR is probably unique for Hbenv and not a common route for uptake of exogenous Ag by APCs. Nevertheless, these data and our studies provide evidence that uptake of exogenous Ag by receptor-mediated endocytosis supplies peptides to the class I and class II processing pathways.

By contrast to transferrin-mediated uptake, B cells lacking mlg<sub>MTP</sub> receptors did not present TNP-OVA to CD8<sup>+</sup> T cells, nor did B cells expressing mlg<sub>MTP</sub> receptors present unmodified OVA to CD8<sup>+</sup> T cells. Similar results were obtained with insulin-specific CTLs, demonstrating that this form of presentation is not limited to OVA or CD8<sup>+</sup>, MHC class I–restricted T cells specific for OVA. Thus, Ags that have no known mechanisms for gaining access to the cytosol can be processed via the class I pathway if Ags are taken up by receptor-mediated endocytosis. How and where the Ags traverse from the endosomal compartment into the cytosol is unknown, but processing is independent of acidification; otherwise, chloroquine would have inhibited class I presentation. This mode of presentation

![Figure 4](image)
may be analogous to the transfer of Ag from phagosomes to the cytosol within macrophages, as demonstrated by other investigators (7, 9).

The physiological consequences of class I processing of exogenous Ag by specific B cells remain to be determined. Many investigators have reported that CD8+ T cells, activated by exogenous Ags, specifically suppress humoral responses and cell-mediated immune responses. This phenomenon has been puzzling, in part, because exogenous Ags were not thought to be processed via the class I pathway. However, macrophages are now known to process exogenous Ag via the class I pathway and Ag bound to invariant (6) or emulsified in CFA (12) prime MHC class I–restricted CD8+ CTLs. Moreover, CD8+ CTLs have been shown to inhibit responses to exogenous Ag by CD4+ T cells in vitro (30) and Ab responses in vivo (12). Inhibition is likely caused by lysis of APCs. Taken together, our data demonstrate that Ag-specific B cells also can serve as targets for regulation by CD8+ T cells.

References

1. Germain, R.N. 1986. The ins and outs of antigen processing and presentation. Nature (Lond.). 322:687-689.
2. Bevan, M.J. 1987. Class discrimination in the world of immunology. Nature (Lond.). 325:192-194.
3. Braciale, T.J., L.A. Morrison, M.T. Sweetser, J. Sambrook, M.J. Gething, and V.L. Braciale. 1987. Antigen presentation pathways to class I and class II MHC–restricted T lymphocytes. ImmunoL Rev. 98:95-114.
4. Rock, K.L., S. Gamble, and L. Rothstein. 1990. Presentation of exogenous antigen with class I major histocompatibility complex molecules. Science (Wash. DC). 249:918-921.
5. Rock, K.L., L. Rothstein, S. Gamble, and C. Fleischacker. 1993. Characterization of antigen–presenting cells that present exogenous antigens in association with class I MHC molecules. J. Exp. Med. 178:438-446.
6. Kovacsovics-Bankowski, M., K. Clark, B. Benacerraf, and K.L. Rock. 1993. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl. Acad. Sci. USA. 90:4942-4946.
7. Pfeifer, J.D., M.J. Wick, R.L. Roberts, K. Findlay, S.J. Norman, and C.V. Harding. 1993. Phagocytic processing of bacterial antigens for class I MHC presentation to T cells. Nature (Lond.). 361:359-362.
8. Reis e Sousa, C., and R.N. Germain. 1995. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med. 182:841-851.
9. Kovacsovics-Bankowski, M., and K.L. Rock. 1995. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science (Wash. DC). 267:243-246.
10. Rock, K.L., B. Benacerraf, and A.K. Abbas. 1984. Antigen presentation by hapten–specific B lymphocytes. I. Role of surface immunoglobulin receptors. J. Exp. Med. 160:102-1113.
11. Yefenof, E., R. Zehavi-Feferman, and R. Guy. 1990. Control of primary and secondary antibody responses by cytotoxic T lymphocytes specific for a soluble antigen. Eur. J. Immunol. 20:1849-1853.
12. Ke, Y., Y. Li, and J.A. Kapp. 1995. Ovalbumin injected with complete Freund’s adjuvant stimulates cytolytic responses. Eur. J. Immunol. 25:549-553.
13. Good, A.H., L. Wofsy, C. Henry, and J. Kimura. 1980. Preparation of hapten-modified protein antigens. In Selected Methods in Cellular Immunology. B.B. Mishell and S.M. Shiigi, editors. W.H. Freeman and Company, San Francisco. 343-350.
14. Hamano, T., K.J. Kim, W.M. Leiserson, and R. Azofsky. 1982. Establishment of B cell hybridomas with B cell surface antigens. J. Immunol. 122:1940-1946.
15. Li, Y., Y. Ke, and J.A. Kapp. 1994. Delivery of exogenous antigen into the major histocompatibility complex class I and class II pathways by electroporation. J. Leukocyt. Biol. 56:616-624.
16. Ochi, A., R.G. Hawley, T. Hawley, M.J. Shulman, A. Traunecker, G. Koehler, and N. Hozumi. 1983. Functional immunoglobulin M production after transfection of cloned immunoglobulin heavy and light chain genes into lymphoid cells. Proc. Natl. Acad. Sci. USA. 80:6351-6353.
17. Moore, M.W., F.R. Carbone, and M.J. Bevan. 1988. Introduction of soluble protein into the class I pathway of antigen processing and presentation. Cell. 54:777-785.
18. Ke, Y., and J.A. Kapp. 1996. Oral antigen inhibits priming of CD8+ CTL, CD4+ T cells and antibody responses while activating CD8+ suppressor T cells. J. Immunol. 156:916.
19. Watanabe, M., D.R. Wegmann, A. Ochi, and N. Hozumi. 1986. Antigen presentation by a B-cell line transfected with cloned immunoglobulin heavy- and light-chain genes specific for a defined hapten. Proc. Natl. Acad. Sci. USA. 83:5247-
20. Watson, J. 1979. Continuous proliferation of murine antigen-specific helper T lymphocytes in culture. *J. Exp. Med.* 150:1510–1519.

21. Roehm, N.W., G.H. Rodgers, S.M. Hatfield, and A.L. Glasbrook. 1991. An improved colorimetric assay for cell proliferation and viability utilizing the tetrazolium salt XTT. *J. Immunol. Methods.* 142:257–265.

22. Stockdale, A.M., J.L. Dul, D.L. Wiest, M. Digel, and Y. Argon. 1987. The expression of membrane and secreted immunoglobulin during the in vitro differentiation of the murine B cell lymphoma CH12. *J. Immunol.* 139:3527–3535.

23. Guise, J.W., P.L. Lim, D. Yuan, and P.W. Tucker. 1988. Alternative expression of secreted and membrane forms of immunoglobulin mu-chain is regulated by transcriptional termination in stable plasmacytoma transfectants. *J. Immunol.* 140:3988–3994.

24. Shinohara, N., M. Watanabe, D.H. Sachs, and N. Hozumi. 1988. Killing of antigen-reactive B cells by class II-restricted, soluble antigen-specific CD8+ cytolytic T lymphocytes. *Nature (Lond.)* 336:481–484.

25. Nuchtern, J.G., J.S. Bonifacino, W.E. Biddison, and R.D. Klausner. 1989. Brefeldin A implicates egress from endoplasmic reticulum in class I-restricted antigen presentation. *Nature (Lond.)* 339:223–226.

26. Rock, K.L., C. Gramm, L. Rothstein, K. Clark, R. Stein, L. Dick, D. Hwang, and A.L. Goldberg. 1994. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. *Cell.* 78:761–771.

27. Barnaba, V., A. Franco, A. Alberti, R. Benvenuto, and F. Balsano. 1990. Selective killing of hepatitis B envelope antigen-specific B cells by class I-restricted, exogenous antigen-specific T lymphocytes. *Nature (Lond.)* 345:258–260.

28. Franco, A., M. Paroli, U. Testa, R. Benvenuto, C. Peschle, F. Balsano, and V. Barnaba. 1992. Transferrin receptor mediates uptake and presentation of hepatitis B envelope antigen by T lymphocytes. *J. Exp. Med.* 175:1195–1205.

29. Gagliardi, M.C., R. Nisini, R. Benvenuto, G. De Petrillo, M.L. Michel, and V. Barnaba. 1994. Soluble transferrin mediates targeting of hepatitis B envelope antigen to transferrin receptor and its presentation by activated T cells. *Eur. J. Immunol.* 24:1372–1376.

30. Rock, K.L., L. Rothstein, C. Fleischacker, and S. Gamble. 1992. Inhibition of class I and class II MHC-restricted antigen presentation by cytotoxic T lymphocytes specific for an exogenous antigen. *J. Immunol.* 148:3028–3033.